<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区
          English 中文網 漫畫網 愛新聞iNews 翻譯論壇
          中國網站品牌欄目(頻道)
          當前位置: Language Tips > Normal Speed News VOA常速

          Scientists seek HIV vaccine using monkey model

          [ 2012-09-18 10:57] 來源:中國日報網     字號 [] [] []  
          免費訂閱30天China Daily雙語新聞手機報:移動用戶編輯短信CD至106580009009

          Get Flash Player

          Download

          Traditional vaccine methods have been unsuccessful in preventing infection by HIV, the virus that causes AIDS. New techniques are being studied to boost antibodies or other parts of the immune system. But researchers are also working on a method to keep the immune system constantly on guard against HIV.

          There are two traditional methods for creating a vaccine. One uses a weakened or attenuated version of a live virus to generate an immune response. The other uses a dead virus. Both methods are proven safe and effective, except when it comes to HIV. Vaccine candidates using these methods simply have not been successful in people when it comes to the AIDS virus.

          “HIV has been a very difficult target for a vaccine for a variety of reasons. It’s designed to evade the immune response by evolution,” said Dr. Louis Picker, associate director of Oregon Health and Science University.

          While attempts to make an HIV vaccine from a dead virus have failed, Picker said, using a weakened virus holds clues and possibilities when used in primates.

          “The live attenuated approach actually was shown to work 20 years ago. But the problem with it was the live attenuated vaccines that actually worked were actually still pathogenic. So they weren’t safe and they could not be moved into humans. This was demonstrated in the non-human primate models – monkey model of AIDS using the virus SIV,” he said.

          SIV stands for simian immunodeficiency virus.

          “These SIVs that were attenuated, that prevented subsequent infection with the full pathogenic virus, still could cause disease. And people found that if you attenuated them anymore, they didn’t work anymore,” he said.

          Picker and his colleagues wanted to understand why the weakened virus offered protection from infection. But at the same time, they needed to prevent it from itself causing disease. They found the answer has to do with T cells, which attack viruses. The weakened, but persistent virus vaccines somehow caused T cells to be ever vigilant. But if the virus was weakened too much, the T cells were not triggered to attack. They concluded that an “effective HIV vaccine might have to persist in the body.”

          Picker said, “The unique aspect of the live attenuated vaccines that seem to work was that they were persistent. They weren’t cleared by the host immune system, but they were able to stick around. Of course in the case of HIV/SIV that’s a bad thing, because eventually those live attenuated vaccines would gain strength and cause disease. But probably the fundamental reason, at least what I hypothesized, that they would be able to elicit protection was because of that persistence.”

          So, they looked for another persistent virus that was not pathogenic, which might generate T cell immune response.

          “The virus that we selected was a virus called cytomegalovirus (CMV), which is actually a virus from a different family of viruses altogether, but it’s one that most people in the world are infected with. But it’s unique in that you can re-infect these people with a virus that now has within its genes HIV genes and then the body would make immune responses to those HIV genes,” he said.

          The HIV genes that would be placed in the harmless virus, he said, would not cause disease.

          “When they’re introduced into the vaccinee, the immune response recognizes these HIV bits as if they’re part of CMV and raises immune response to it,” he said.

          That’s the plan, anyway. The difficult part is making a version of the vaccine that’s safe and effective for humans. That requires an approved vaccine candidate and years of clinical trials.

          Meanwhile, in Thailand, a follow-up study is getting underway of the RV 144 vaccine candidate. Several years ago, a study showed that it did indeed provide some measure of protection against HIV, but not enough, being only 31 percent effective. A clinical study called RV 305 will use the same vaccine components as RV 144, but will attempt to boost and extend the immune response through antibodies.

          相關閱讀

          Tensions rising again over Iran's nuclear program(視頻)

          Mideast protests spark debate over free speech, religion(視頻)

          The Occupy Movement turns one

          American's first exchange students from China

          (來源:VOA 編輯:Julie)

           
          中國日報網英語點津版權說明:凡注明來源為“中國日報網英語點津:XXX(署名)”的原創作品,除與中國日報網簽署英語點津內容授權協議的網站外,其他任何網站或單位未經允許不得非法盜鏈、轉載和使用,違者必究。如需使用,請與010-84883631聯系;凡本網注明“來源:XXX(非英語點津)”的作品,均轉載自其它媒體,目的在于傳播更多信息,其他媒體如需轉載,請與稿件來源方聯系,如產生任何問題與本網無關;本網所發布的歌曲、電影片段,版權歸原作者所有,僅供學習與研究,如果侵權,請提供版權證明,以便盡快刪除。
           

          關注和訂閱

          人氣排行

          翻譯服務

          中國日報網翻譯工作室

          我們提供:媒體、文化、財經法律等專業領域的中英互譯服務
          電話:010-84883468
          郵件:translate@chinadaily.com.cn
           
           
          主站蜘蛛池模板: 在线看av一区二区三区| www插插插无码视频网站| 破了亲妺妺的处免费视频国产| 91精品国产综合久久精品| 久久婷婷五月综合97色一本一本 | 亚洲av成人无码天堂| 国产v亚洲v天堂a无码99| 毛片一区二区在线看| 亚洲AV国产福利精品在现观看| 国产免费视频一区二区| 日日猛噜噜狠狠扒开双腿小说| 日韩V欧美V中文在线| 国产精品一区二区三区四区| www国产精品内射熟女| 手机看片AV永久免费| 国产精品国产精品偷麻豆| 99久久精品美女高潮喷水| 亚洲国产日韩A在线亚洲| 亚洲av本道一区二区| 粉嫩一区二区三区粉嫩视频| 中文字幕有码日韩精品| 亚洲二区中文字幕在线| 日韩国产亚洲一区二区三区| 91精品国产三级在线观看| 性欧美在线| 国产精品久久久久aaaa| 97在线视频人妻无码| 视频一区视频二区卡通动漫| 久久久亚洲欧洲日产国码农村| 国产真人无码作爱视频免费| 夜夜添狠狠添高潮出水| 丝袜足控一区二区三区| av在线播放观看免费| 成人国产乱对白在线观看| 国产精品国产三级国产专业| 亚洲精品韩国一区二区| 色爱综合另类图片av| 国模粉嫩小泬视频在线观看| 国产精品自在在线午夜区app| 亚洲肥老太bbw| 久久99久国产精品66|